



(11) **EP 1 420 827 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 84

(48) Corrigendum issued on:
23.12.2009 Bulletin 2009/52

(45) Date of publication and mention
of the grant of the patent:
23.09.2009 Bulletin 2009/39

(21) Application number: **02794796.9**

(22) Date of filing: **16.08.2002**

(51) Int Cl.:
A61K 47/18 (2006.01) A61K 38/29 (2006.01)
A61P 19/08 (2006.01) A61P 19/10 (2006.01)

(86) International application number:
PCT/EP2002/009181

(87) International publication number:
WO 2003/015822 (27.02.2003 Gazette 2003/09)

(54) **5-CNAC AS ORAL DELIVERY AGENT FOR PARATHYROID HORMONE FRAGMENTS**

5-CNAC ZUR ORALEN VERABREICHUNG VON PARATHORMONFRAGMENTEN

5-CNAC UTILISE EN TANT QU'AGENT D'ADMINISTRATION PAR VOIE ORALE POUR DES
FRAGMENTS D'HORMONE PARATHYROIDIENNE

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
IE IT LI LU MC NL PT SE SK TR**
Designated Extension States:
RO SI

(30) Priority: **17.08.2001 US 313048 P**

(43) Date of publication of application:
26.05.2004 Bulletin 2004/22

(73) Proprietors:
• **Novartis AG**
4056 Basel (CH)
Designated Contracting States:
**BE BG CH CY CZ DE DK EE ES FI FR GB GR IE
IT LI LU MC NL PT SE SK TR**
• **Novartis Pharma GmbH**
1230 Wien (AT)
Designated Contracting States:
AT

(72) Inventors:
• **AZRIA, Moise**
CH-4054 Basel (CH)

• **BATEMAN, Simon, David**
Randolph, NJ 07869 (US)

(74) Representative: **de Weerd, Petrus G.W. et al**
c/o Novartis AG, Geistiges Eigentum Konzern CH
4002 Basel (CH)

(56) References cited:
WO-A-00/59863 WO-A-94/07514
US-A- 5 773 647

• **LEONE-BAY A ET AL: "ORAL DELIVERY OF
BIOLOGICALLY ACTIVE PARATHYROID
HORMONE" PHARMACEUTICAL RESEARCH,
NEW YORK, NY, US, vol. 18, no. 7, July 2001
(2001-07), pages 964-970, XP001106035 ISSN:
0724-8741**
• **LEONE-BAY A ET AL: "SYNTHESIS AND
EVALUATION OF COMPOUNDS THAT
FACILITATE THE GASTROINTESTINAL
ABSORPTION OF HEPARIN" JOURNAL OF
MEDICINAL CHEMISTRY, AMERICAN CHEMICAL
SOCIETY, US, vol. 41, no. 7, 26 March 1998
(1998-03-26), pages 1163-1171, XP001018961
ISSN: 0022-2623**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).